Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Black Diamond Therapeutics (BDTX), a clinical-stage oncology company focused on developing MasterKey therapies for cancer patients, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Mark Velleca will engage in a fireside chat on June 4, 2025 from 4:20-4:50pm ET in New York. The company will also conduct one-on-one investor meetings during the event. A webcast of the presentation will be accessible through Black Diamond's website and remain archived for 90 days post-event.
Black Diamond Therapeutics (BDTX), un'azienda oncologica in fase clinica specializzata nello sviluppo di terapie MasterKey per pazienti affetti da cancro, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. L'amministratore delegato Mark Velleca parteciper脿 a una conversazione informale il 4 giugno 2025 dalle 16:20 alle 16:50 ET a New York. Durante l'evento, l'azienda terr脿 anche incontri individuali con gli investitori. La presentazione sar脿 trasmessa in webcast sul sito web di Black Diamond e rester脿 disponibile in archivio per 90 giorni dopo l'evento.
Black Diamond Therapeutics (BDTX), una empresa oncol贸gica en etapa cl铆nica enfocada en desarrollar terapias MasterKey para pacientes con c谩ncer, ha anunciado su participaci贸n en la pr贸xima Jefferies Global Healthcare Conference. El CEO Mark Velleca participar谩 en una charla informal el 4 de junio de 2025 de 4:20 a 4:50 pm ET en Nueva York. La empresa tambi茅n realizar谩 reuniones individuales con inversores durante el evento. La presentaci贸n estar谩 disponible en webcast a trav茅s del sitio web de Black Diamond y permanecer谩 archivada por 90 d铆as despu茅s del evento.
Black Diamond Therapeutics (BDTX)電� 鞎� 頇橃瀽毳� 鞙勴暅 MasterKey 旃橂氩� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠鞚� 膦呾枒頃� 須岇偓搿�, 雼り皜鞓る姅 Jefferies Global Healthcare Conference鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. CEO Mark Velleca電� 2025雲� 6鞗� 4鞚� 雺挫殨鞐愳劀 霃欕秬 響滌鞁� 旮办 鞓ろ泟 4鞁� 20攵勲秬韯� 4鞁� 50攵勱箤歆� 歆勴枆霅橂姅 頇旉赴鞎犾暊頃� 雽�頇旍棎 彀胳棳頃� 鞓堨爼鞛呺媹雼�. 須岇偓電� 頄夓偓 旮瓣皠 霃欖晥 鞚茧寑鞚� 韴瀽鞛� 氙疙寘霃� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 氚滍憸 webcast電� Black Diamond 鞗轨偓鞚错姼毳� 韱淀暣 鞁滌箔頃� 靾� 鞛堨溂氅�, 頄夓偓 膦呺 頉� 90鞚缄皠 鞎勳勾鞚措笇搿� 鞝滉车霅╇媹雼�.
Black Diamond Therapeutics (BDTX), une soci茅t茅 oncologique en phase clinique sp茅cialis茅e dans le d茅veloppement de th茅rapies MasterKey pour les patients atteints de cancer, a annonc茅 sa participation 脿 la prochaine Jefferies Global Healthcare Conference. Le PDG Mark Velleca participera 脿 une discussion informelle le 4 juin 2025 de 16h20 脿 16h50 (heure de l'Est) 脿 New York. La soci茅t茅 tiendra 茅galement des r茅unions individuelles avec des investisseurs pendant l'茅v茅nement. Une diffusion en webcast de la pr茅sentation sera accessible via le site web de Black Diamond et restera archiv茅e pendant 90 jours apr猫s l'茅v茅nement.
Black Diamond Therapeutics (BDTX), ein klinisch fortgeschrittenes Onkologieunternehmen, das sich auf die Entwicklung von MasterKey-Therapien f眉r Krebspatienten spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference bekanntgegeben. CEO Mark Velleca wird am 4. Juni 2025 von 16:20 bis 16:50 Uhr ET in New York an einem informellen Gespr盲ch teilnehmen. Das Unternehmen wird w盲hrend der Veranstaltung auch Einzelgespr盲che mit Investoren f眉hren. Ein Webcast der Pr盲sentation wird 眉ber die Website von Black Diamond zug盲nglich sein und f眉r 90 Tage nach der Veranstaltung archiviert bleiben.
- None.
- None.
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025 in New York, NY. In addition, the company will host one-on-one meetings with investors on the same day.
Presentation details are as follows:
- 4:20-4:50pm ET on Wednesday, June 4
The Webcast will be available at the start of the presentation on the investor relations section of the Company鈥檚 website, . A replay of the webcast will also be available and archived for 90 days following the event.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company鈥檚 MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. For more information, please visit听.
Contacts
For Investors:
For Media:
听
FAQ
When is Black Diamond Therapeutics (BDTX) presenting at the Jefferies Healthcare Conference 2025?
Who will represent BDTX at the Jefferies Global Healthcare Conference 2025?
How can investors access Black Diamond Therapeutics' Jefferies conference presentation?
What type of company is Black Diamond Therapeutics (BDTX)?
